Biography: Dr. Saurabh Agarwal is an Associate Professor of Pharmaceutical Sciences at St. John's University, New York, where he leads a highly productive translational research program dedicated to developing innovative targeted therapies for pediatric cancers. He is the recipient of numerous prestigious honors, including the NIH Research Enhancement Award, the St. Baldrick's Foundation Scholar Career Award, multiple Hero Awards, and the Knight Commander designation in recognition of his contributions to pediatric oncology. His discoveries have led to several high-impact publications and a multi-institutional clinical trial inspired by his discovery of the neuroblastoma cancer stem cells. Dr. Agarwal also serves on the editorial boards of several leading journals, including *Scientific Reports*, *Translational Oncology*, *Cancers*, *Cells*, and *Pharmaceutics*.

A nationally recognized leader in cancer pharmacology, Dr. Agarwal serves on the Executive Committee of the ASPET Division for Cancer Pharmacology, the Mentoring and Career Development Committee, and is a member of the Organizing Committees for the ASPET 2025 and 2026 Annual Conferences. He is the Founding President of NYSPET (New York Society of Pharmacology and Experimental Therapeutics), and the founder of ventures focused on advancing pediatric cancer drug discovery and translational innovation. A passionate educator and mentor, Dr. Agarwal has trained numerous graduate and undergraduate students, many of whom have received national fellowships, awards, and research recognitions. He remains deeply committed to fostering the next generation of cancer researchers and to promoting science through public outreach, advocacy, and fundraising for childhood cancer research.

Title: Transforming Pediatric Cancer Therapy: AI-Based Discovery and Epigenetic Interventions in Neuroblastoma"

Impact Statement(s)-

For Faculty Members-

Dr. Saurabh Agarwal's seminar will provide faculty members with a comprehensive overview of emerging interdisciplinary approaches that integrate artificial intelligence-driven drug discovery with epigenetic-based therapeutic development, with direct applications to pediatric oncology. As a translational pharmacologist at St. John's University (New York) and founder of scientific and academic ventures, Dr. Agarwal brings a unique perspective on how academic research can evolve into therapeutic pipelines

and industry-facing innovation. His talk will highlight recent advances from his lab in building AI-powered discovery platforms and targeting chromatin-based mechanisms in neuroblastoma. The session will be particularly relevant for faculty engaged in drug discovery, molecular biology, systems medicine, and translational biosciences. Faculty members are encouraged to attend and interact with Dr. Agarwal to explore opportunities for scientific collaboration, joint grant initiatives, and the development of research partnerships at the interface of computation, epigenetics, and pediatric cancer therapeutics.

For Students-

Dr. Saurabh Agarwal's seminar will take students to the forefront of biomedical innovation, showcasing how artificial intelligence and epigenetic science are transforming the discovery and development of targeted therapies for pediatric cancers, with a focus on neuroblastoma. A faculty member at St. John's University (New York) and founder of scientific ventures, Dr. Agarwal brings an interdisciplinary perspective that bridges computational biology, molecular pharmacology, and translational research. In this talk, he will share recent advances from his lab in developing AI-powered drug discovery pipelines and epigenetic-based therapeutic strategies. The session will be particularly valuable for students interested in biotechnology, molecular medicine, systems biology, and translational therapeutics. All students are encouraged to attend and may engage in informal discussion with Dr. Agarwal following the seminar.